Companies
MedChemExpress LLC (MCE)
Products
MedChemExpress - Model Manumycin A - ...

MedChemExpress - Model Manumycin A - 52665-74-4

Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion[1][3][4].

Manumycin A

MCE China：Manumycin A

Brand：MedChemExpress (MCE)

Cat. No.HY-N6796

CAS：52665-74-4

Purity：99.27%

Storage：-20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion.

In Vitro：Manumycin A (0.25-5 μM, 24 h) downregulates the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, thus possessing potential anti-inflammatory properties[1]. Manumycin A (0-25 μM, 72 h) can enhance its inhibitory effect on lung cancer cells after inhibiting HSF1 mediated heat shock response (HSR)[2]. Manumycin A (5 μM, 72 h) inhibits the growth of triple negative breast cancer cells through LC3 mediated cytoplasmic vacuolation death[3]. Manumycin A (250 nM, 48 h) inhibits exosome biogenesis and secretion by targeting Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells[4].

In Vivo：Manumycin A (5 mg/kg; once every two days; 2 weeks; i.p.) has anti-tumor effect in triple negative breast cancer mice[3]. Manumycin A (3 μg; once; i.m.) can correct abnormal splicing of Clcn1 in type 1 myotonic dystrophy (DM1) mice[5].

IC50 & Target：TrxR-1[1], Ras[4] In Vitro Manumycin A (0.25-5 μM, 24 h) downregulates the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, thus possessing potential anti-inflammatory properties[1]. Manumycin A (0-25 μM, 72 h) can enhance its inhibitory effect on lung cancer cells after inhibiting HSF1 mediated heat shock response (HSR)[2]. Manumycin A (5 μM, 72 h) inhibits the growth of triple negative breast cancer cells through LC3 mediated cytoplasmic vacuolation death[3]. Manumycin A (250 nM, 48 h) inhibits exosome biogenesis and secretion by targeting Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells[4]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Manumycin A Related Antibodies Real Time qPCR[1]. Cell Line: Human monocytic leukemia cells THP-1

References：

[1]. Cecrdlova E, et al. Manumycin A downregulates release of proinflammatory cytokines from TNF alpha stimulated human monocytes. Immunol Lett. 2016 Jan;169:8-14. [Content Brief]

[2]. Sojka DR, et al. Inhibition of the Heat Shock Protein A (HSPA) Family Potentiates the Anticancer Effects of Manumycin A. Cells. 2021 Jun 7;10(6):1418. [Content Brief]

[3]. Singha PK, et al. Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death. Cell Death Dis. 2013 Jan 17;4(1):e457.

[4]. Datta A, et al. Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells. Cancer Lett. 2017 Nov 1;408:73-81. [Content Brief]

[5]. Oana K, et al. Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice. Sci Rep. 2013;3:2142. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。